Vivos Therapeutics (NASDAQ:VVOS) shares rallied premarket on Wednesday after the medtech firm gained first ever FDA 510(k) clearance for oral device treatment of severe obstructive sleep apnea (OSA).

Vivos adds more cutting-edge products to its roster serving the breathing and sleep wellness market LITTLETON, Colo., Feb. 05, 2026 (GLOBE ...

Vivos Therapeutics, Inc. has announced that its VidaSleep™ oral appliance, equipped with FDA-cleared Unilateral Bite Block technology, has received approval from the Centers for Medicare & Medicaid ...

LITTLETON, Colo., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (VVOS), a leading medical device and technology company specializing in the development and commercialization of highly ...

Kennewick, WA, July 14, 2025 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), a pioneer in Precision Radionuclide TherapyTM (PRnT) solutions, today announced the submission of its Investigational Device ...

(Reuters) -Vivos Therapeutics said on Wednesday the U.S. health regulator has cleared its oral device for severe obstructive sleep apnea (OSA), leading a massive rally in the company's shares before ...

LITTLETON, Colo., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ:VVOS), a leading medical device and technology company specializing in the development ...

Vivos becomes the first company with clear alternative treatment to CPAP or surgical neurostimulation implants for severe OSA The average treatment time was just 9.7 months, with 80% of patients ...

Nov 29 (Reuters) - Vivos Therapeutics (VVOS.O), opens new tab said on Wednesday the U.S. health regulator has cleared its oral device for severe obstructive sleep apnea (OSA), leading a massive rally ...

LITTLETON, Colo., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and technology company specializing in the ...